Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

UBTD1 Drives Ovarian Cancer Progression and Chemoresistance via the TNF/AP-1 Signaling Axis

ABSTRACT: The ubiquitin domain-containing protein 1 (UBTD1), a protein involved in degradation and cell cycle regulation, is gaining recognition for its role in tumorigenesis. Ovarian cancer (OC) is the deadliest gynecological cancer, characterized by poor prognosis due to aggressive growth and chemoresistance. This study investigates the role of UBTD1 in OC pathogenesis. UBTD1 expression and prognosis were analyzed using public databases such as the Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO). UBTD1 was knocked down via Short hairpin RNA (shRNA) in A2780 and SKOV3 cells. Functional impacts on proliferation, migration, cell cycle, and apoptosis were assessed. RNA sequencing and Quantitative reverse transcription polymerase chain reaction (qRT-PCR) were used to investigate downstream pathways. UBTD1 is markedly overexpressed in OC and correlates with reduced survival. Its knockdown suppressed proliferation, migration, and invasion, induced G0/G1 arrest (upregulating p21, downregulating Cyclin D1), and enhanced cisplatin sensitivity. Transcriptome analysis revealed downregulation of the tumor necrosis factor (TNF) pathway and activator protein-1 (AP-1) factors FOS/FOSB. Ectopic FOS expression rescued the malignant phenotypes. UBTD1 drives OC progression and chemoresistance, potentially through the TNF/AP-1 axis, emerging as a prognostic biomarker and therapeutic target.

ORGANISM(S): Homo sapiens

PROVIDER: GSE325761 | GEO | 2026/07/29

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

5-methylcytosine regulated CCNL2 promotes cisplatin resistance by ferroptosis inhibition in ovarian cancer

Project description:Ovarian cancer (OC) is the most lethal gynecological tumor, primarily due to resistance to chemotherapy. Cyclin L2 (CCNL2), a novel member of the cyclin family, plays an important role in HIV replication. However, its role in OC chemoresistance remains unknown. Here, we demonstrate that elevated expression of CCNL2 indicates a poor prognosis in ovarian cancer. Furthermore, inhibition of CCNL2 reduces malignancy and enhances chemotherapy sensitivity in OC. Additionally, CCNL2 inhibition promotes cisplatin-induced ferroptosis by increasing intracellular iron ion levels. Mechanistically, CCNL2 is upregulated by YBX1 via a 5-methylcytosine (m5C) manner, leading to increased CCNL2 mRNA stability. Given the lack of protein structure data for CCNL2, we performed virtual screening to identify YBX1 inhibitors, targeting its upstream regulation. The inhibitor YB-B1 effectively suppresses YBX1 and CCNL2 expression, and enhances the cytotoxic effect of cisplatin. Together, we highlight the critical role of CCNL2 in ovarian cancer chemoresistance, elucidate its regulatory mechanism, and propose a new approach to address the challenge.

2025-06-25 | GSE279620 | GEO

Interplay between AP-1 and ERalpha in regulating gene expression and proliferation networks in breast cancer cells

Project description:Estrogen receptor alpha (ERalpha) is a ligand-dependent transcription factor that plays an important role in breast cancer. Estrogen-dependent gene regulation by ERalpha can be mediated by interaction with other DNA-binding proteins, such as activator protein-1 (AP-1). The nature of such interactions in mediating the estrogen response in breast cancer cells remains unclear. Here we show that knockdown of c-Fos, a component of the transcription factor AP-1, attenuates the expression of 37% of all estrogen-regulated genes, suggesting that AP-1 is a fundamental factor for ERalpha-mediated transcription. Additionally, knockdown of c-Fos affected the expression of a number of genes that were not regulated by estrogen. Pathway analysis reveals that silencing of c-Fos downregulates an E2F1-dependent pro-proliferative gene network. Thus, modulation of the E2F1 pathway by c-Fos represents a novel mechanism by which c-Fos enhances breast cancer cell proliferation. Furthermore, we show that c-Fos and ERalpha can cooperate in regulating E2F1 gene expression by binding to regulatory elements in the E2F1 promoter. To start to dissect the molecular details of the cross-talk between AP-1 and estrogen signaling, we identify a novel ERalpha/AP-1 target, PKIB (cAMP-dependent protein kinase inhibitor-beta), which is overexpressed in ERalpha-positive breast cancer tissues. Knockdown of PKIB by siRNA results in drastic growth suppression of breast cancer cells. Collectively, our findings support AP-1 as a critical factor that governs estrogen-dependent gene expression and breast cancer proliferation programs. MCF-7 cells were transfected with a control siRNA or with the pool of siRNAs targeting c-Fos for 72 h and were then treated with vehicle or E2 for 24 h, and global gene expression profiles were assessed. Three or four biological replicates were used for each group.

2012-08-05 | E-GEOD-36586 | biostudies-arrayexpress

Essential role of PLD2 in hypoxia-induced stemness and therapy resistance in ovarian tumors

Project description:Ovarian cancer (OC) is the most lethal gynecological cancer due to its late diagnosis and, importantly, its high rate of chemoresistance. Hypoxia in solid tumors is an important source of chemoresistance that can determine poor patient prognosis. Such chemoresistance relies on the presence of cancer stem cells (CSCs), and hypoxia promotes their generation through transcriptional activation by HIF transcription factors. We use OC cell lines, xenograft models, OC patient samples, transcriptional databases, iPSCs and ATAC-seq. We show here that hypoxia induces the formation of ovarian CSCs through transcriptional activation of the PLD2 gene encoding phospholipase D2. HIF-1 activates PLD2 transcription through hypoxia response elements located within PLD2 promoter and an intronic enhancer. PLD2 overexpression leads to similar effects than hypoxia, increasing CSC-like features, stemness gene expression and enhancing cell reprogramming in OC cells, as well as chromatin accessibility around stemness genes detected by ATAC-seq. Conversely, PLD2 depletion in hypoxia partially suppresses these effects, indicating that PLD2 is a major determinant of hypoxia-induced CSC generation in OC. Indeed, PLD2 expression is high in OC patients leading to poor survival and a transcriptional switch in the genes related to the response to hypoxia and stemness. Finally, we demonstrate that PLD2 overexpression provokes resistance to platinum-based chemotherapy and that combination of cisplatin with pharmacological inhibition of PLD2 suppresses such resistance. Altogether, our work highlights the importance of the HIF-1-PLD2 axis for CSC generation and chemoresistance in OC and proposes an alternative treatment for patients with high PLD2 expression.

2023-08-06 | GSE210599 | GEO

Interplay between AP-1 and ERalpha in regulating gene expression and proliferation networks in breast cancer cells

2012-08-06 | GSE36586 | GEO

A comprehensive analysis of the mechanism of FOS in the progression of endometrialcyst of ovary to endometriosis-associated ovarian cancer

Project description:Background: Endometrialcyst of ovary (EMC) may develop into endometriosis-associated ovarian cancer over time (EAOC). EAOC pathogenesis is unknown. This study investigated the likely mechanism of EAOC publishing related with orthotopic endometrial, searched for a feasible biomarker using RNA sequencing, and examined the molecular function of this biomarker in ectopic endometrial cells from EAOC and EMC patients. Methods: RNA sequencing was performed on 5 EAOC and 4 EMC tissue samples. Differential expression analysis employed RNA-seq data. To identify biomarkers, differential genes were used in PPI network design, GO pathway enrichment, and GSEA pathway enrichment. Immunohistochemical staining revealed FOS expression in various endometrium. Lv-FOS was utilized to up-regulate FOS in hEnSCs, and cell counting kit-8 (CCK-8), colony formation assay, and scratch assay were performed to assess cell viability, proliferation, and migration. Western blot showed protein expression alterations. Results: 249 genes were differently expressed, including FOS. Pathway enrichment study demonstrated that MAPK, AP-1, ERK, and other signaling pathways were involved in EMC-to-EAOC conversion. FOS upregulation in hEnSCs increased cell viability, proliferation, and migration. Western blot results showed that FOS, CDK4, cyclinD1, P21, and invasion-related proteins p-stat3, MMP2, and MMP9 were up- or down-regulated, respectively. Conclusion: Mitosis and cell cycle affect EMC to EAOC progression. FOS expression, a novel biomarker, promotes EMC transition into EAOC and endometrial cell proliferation, invasion, and migration. Keywords: FOS, endometrialcyst of ovary, endometriosis-associated ovarian cancer, biomarker

2023-05-23 | GSE226575 | GEO

JUP drives a PDGFB-JAK-STAT signaling axis to promote ovarian cancer progression

Project description:The Janus kinase (JAK) signaling pathway is frequently associated with ovarian cancer (OC) progression. However, inhibition of JAK signaling has achieved limited therapeutic effects in OC patients, highlighting the need to elucidate the mechanisms underlying JAK dysregulation in OC development. Here, we demonstrate that Junction plakoglobin (JUP) acts as a positive regulator in the JAK signaling pathway in OC. Clinically, JUP expression is significantly upregulated and correlates with poor prognosis in OC patients. Phenotypically, depletion of JUP suppresses OC cell proliferation and migration, whereas overexpression of JUP yielded opposite effects. Mechanistically, JUP drives a PDGFB-JAK-STAT signaling axis through interaction with GABPA. Collectively, our findings establish an oncogenic role of JUP in OC progression via upregulation of JAK signaling and suggest that JUP represents a potential therapeutic target in JAK-driven OC.

2026-07-06 | GSE337668 | GEO

Matrix Gla Protein acts as a driver of stemness and tumor initiation in ovarian cancer

Project description:Ovarian cancer (OC) displays the highest mortality among gynecological tumors, mainly due to early peritoneal dissemination, the high frequency of tumor relapse following primary debulking and the development of chemoresistance. All these events are thought to be initiated and sustained by a subpopulation of neoplastic cells, termed ovarian cancer stem cells (OCSC), that are endowed with self-renewing and tumor-initiating properties. This implies that interfering with OCSC function should offer novel therapeutic perspectives to defeat OC progression. To this aim, a better understanding of the molecular and functional makeup of OCSC in clinically relevant model systems is essential. We have profiled the transcriptome of OCSC vs. their bulk cell counterpart from a panel of patient-derived OC cell cultures. This revealed that Matrix Gla Protein (MGP), classically known as a calcification-preventing factor in cartilage and blood vessels, is markedly enriched in OCSC. Functional assays showed that MGP confers several stemness-associated traits to OC cells, including a transcriptional reprogramming. Patient-derived organotypic cultures pointed to the peritoneal microenvironment as a major inducer of MGP expression in OC cells. Furthermore, MGP was found to be necessary and sufficient for tumor initiation in OC mouse models, by shortening tumor latency and increasing dramatically the frequency of tumor-initiating cells. Mechanistically, MGP-driven OC stemness was mediated by the stimulation of Hedgehog signaling, in particular through the induction of the Hedgehog effector GLI1, thus highlighting a novel MGP/Hedgehog pathway axis in OCSC. Finally, MGP expression was found to correlate with poor prognosis in OC patients, and was increased in tumor tissue after chemotherapy, supporting the clinical relevance of our findings. Thus, MGP is a novel driver in OCSC pathophysiology, with a major role in stemness and in tumor initiation.

2023-05-10 | PXD037543 | Pride

Pigment epithelium–derived factor promotes peritoneal dissemination of ovarian cancer through induction of immunosuppressive macrophages

Project description:Peritoneal dissemination of ovarian cancer (OC) correlates with poor prognosis, but the mechanisms underlying the escape of OC cells from the intraperitoneal immune system have remained unknown. We here identify pigment epithelium–derived factor (PEDF) as a regulator of OC cell dissemination, which functions through induction of CD206+ IL-10–producing macrophages. High PEDF gene expression was associated with poor prognosis in OC patients. Concentrations of PEDF in ascites and serum were significantly higher in OC patients than those with more benign tumors and correlated with early recurrence of OC patients, suggesting that PEDF might serve as a prognostic biomarker. Bromodomain and extraterminal (BET) inhibitors were found to reduce PEDF expression and limit both OC cell survival and CD206+ macrophage induction in the peritoneal cavity. Our results thus implicate PEDF as a driver of OC dissemination and identify a BET protein–PEDF–IL-10 axis as a promising therapeutic target for OC.

2022-04-25 | GSE201275 | GEO

Upregulated mRNAs and lncRNAs in chemoresistant breast cancer

Project description:Chemoresistance is a major cause of poor prognosis of breast cancer.More and more mRNAs and lncRNAs are reported to upregulate chemoresistance in breast cancer.To explore the how mRNAs and lncRNAs involved in chemoresistance of breast cancer,we sceened upregulated mRNAs and lncRNA from parental MCF-7 , chemoresistant MCF-7 cells as well as 4 breast cancer tissue sensitive to chemotherapy and 4 resistant to chemotherapy . Total RNA was extracted using Trizol reagent. Agilent Human lncRNA Microarray V6 (4*180K) was used to analyze the global profiling of human lncRNAs and protein-coding transcripts in these samples. The microarray contains 83,835 lncRNAs and 27,233 coding genes.

2020-02-25 | E-MTAB-8787 | biostudies-arrayexpress

nc886, a TGF-β-induced non-coding RNA, suppresses the microRNA pathway in ovarian cancer

Project description:Transforming growth factor-β (TGF-β) signaling and microRNAs (miRNAs) are important gene regulatory components in cancer. Usually in advanced malignant stages, TGF-β signaling is elevated, but global miRNA expression is suppressed. Such a gene expression signature is well illustrated in a fibrosis/mesenchymal subtype of ovarian cancer (OC) that is of poor prognosis. However, the interplay between the two pathways in the OC subtype has not yet been elucidated. nc886 is a recently identified non-coding RNA implicated in several malignancies. nc886's high expression is associated with the poor prognosis of 285 patients in an OC cohort. Herein we have found in OC that nc886 expression is induced by TGF-β and that nc886 binds to the enzyme Dicer to inhibit the processing of miRNA precursors into mature forms. By preventing the miRNA pathway, nc886 emulates TGF-β in gene expression patterns and potentiates cell adhesion, migration, invasion, and drug resistance. We report nc886 as a novel molecular link between the TGF-β and miRNA pathways.

2017-11-08 | GSE106616 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data